Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human Study of ImmunoPET Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504, an Anti-PD-L1 Tracer for Positron Emission Tomography in Patients With Advanced Thoracic Malignancies

Trial Profile

A Phase 1, First-in-Human Study of ImmunoPET Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504, an Anti-PD-L1 Tracer for Positron Emission Tomography in Patients With Advanced Thoracic Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Zirconium 89 DFO REGN 3504 (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Thoracic neoplasms
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 2 Dec 2020 to 4 Jun 2021.
    • 08 Jan 2019 Planned primary completion date changed from 3 Nov 2020 to 6 May 2021.
    • 08 Jan 2019 Planned initiation date changed from 10 Dec 2018 to 10 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top